4.8 Article

Pervasive chromosomal instability and karyotype order in tumour evolution

期刊

NATURE
卷 587, 期 7832, 页码 126-+

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41586-020-2698-6

关键词

-

资金

  1. Francis Crick Institute from Cancer Research UK [FC001169, FC010110, FC001202]
  2. UK Medical Research Council [FC001169, FC010110, FC001202]
  3. Wellcome Trust [FC001169, FC010110, FC001202, 211179/Z/18/Z]
  4. Marie Curie ITN Project PLOIDYNET (FP7-PEOPLE-2013) [607722]
  5. Breast Cancer Research Foundation (BCRF)
  6. Royal Society Research Professorships Enhancement Award [RP/EA/180007]
  7. Foulkes Foundation
  8. NovoNordisk Foundation [ID 16584]
  9. Aarhus University Research Foundation
  10. European Research Council [FP7-THESEUS-617844, PROTEUS-835297]
  11. European Union's Horizon 2020 research and innovation program (Marie Sklodowska-Curie grant [703594-DECODE]
  12. UK Medical Research Council Skills Development Fellowship Award [MR/P014712/1]
  13. Wellcome Trust Clinical Career Development Fellowship [214584/Z/18/Z]
  14. CRUK Early Detection Pump Prime Award
  15. NCI Outstanding Investigatory Award [1R35CA220481]
  16. Swedish Cancer Society
  17. Swedish Research Council
  18. Berta Kamprad Foundation
  19. National Breast Cancer Foundation of Australia Endowed Chair
  20. Breast Cancer Research Foundation, New York
  21. Cancer Research UK [C50947/A18176]
  22. National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden Hospital and Institute of Cancer Research [A109]
  23. Kidney and Melanoma Cancer Fund of The Royal Marsden Cancer Charity
  24. The Rosetrees Trust [A2204]
  25. National Institute for Health Research
  26. Rosetrees Trust
  27. UKI NETs
  28. NIHR University College London Hospitals Biomedical Research Centre
  29. Office of the Director, the National Institutes of Health [DP5OD026395]
  30. Department of Defense Breast Cancer Research Breakthrough Award [W81XWH-16-1-0315, BC151244]
  31. Burroughs Wellcome Fund Career Award for Medical Scientists
  32. Parker Institute for Immunotherapy at MSKCC
  33. Josie Robertson Foundation
  34. MSKCC core grant [P30-CA008748]
  35. Helmholtz Association (Germany)
  36. Royal Society [211179/Z/18/Z]
  37. NIHR BRC at University College London Hospitals
  38. CRUK University College London Experimental Cancer Medicine Centre
  39. Cancer Research UK (TRACERx)
  40. Cancer Research UK (PEACE)
  41. Cancer Research UK (CRUK Cancer Immunotherapy Catalyst Network)
  42. Cancer Research UK Lung Cancer Centre of Excellence
  43. Butterfield Trust
  44. Stoneygate Trust
  45. CRUK-UCL Centre, Experimental Cancer Medicine Centre
  46. Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant [SU2C-AACR-DT23-17]
  47. Stand Up To Cancer is a program of the Entertainment Industry Foundation
  48. American Association for Cancer Research
  49. Scientific Partner of SU2C
  50. European Research Council (ERC) under the European Union's Seventh Framework Programme (FP7/2007-2013) Consolidator Grant [FP7-THESEUS-617844]
  51. European Commission ITN FP7-PloidyNet [607722]
  52. ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020 research and innovation programme [835297]
  53. Chromavision from the European Union's Horizon 2020 research and innovation programme [665233]
  54. Medical Research Council [MR/L016311/1]
  55. High-Performance Computing at the Francis Crick Institute
  56. UCL Department of Computer Science Cluster
  57. Medical Research Council [MR/L016311/1] Funding Source: researchfish
  58. MRC [MR/P014712/1, MR/L016311/1] Funding Source: UKRI
  59. Wellcome Trust [214584/Z/18/Z] Funding Source: Wellcome Trust

向作者/读者索取更多资源

Chromosomal instability in cancer consists of dynamic changes to the number and structure of chromosomes(1,2). The resulting diversity in somatic copy number alterations (SCNAs) may provide the variation necessary for tumour evolution(1,3,4). Here we use multi-sample phasing and SCNA analysis of 1,421 samples from 394 tumours across 22 tumour types to show that continuous chromosomal instability results in pervasive SCNA heterogeneity. Parallel evolutionary events, which cause disruption in the same genes (such asBCL9, MCL1,ARNT(also known asHIF1B),TERTandMYC) within separate subclones, were present in 37% of tumours. Most recurrent losses probably occurred before whole-genome doubling, that was found as a clonal event in 49% of tumours. However, loss of heterozygosity at the human leukocyte antigen (HLA) locus and loss of chromosome 8p to a single haploid copy recurred at substantial subclonal frequencies, even in tumours with whole-genome doubling, indicating ongoing karyotype remodelling. Focal amplifications that affected chromosomes 1q21 (which encompassesBCL9, MCL1andARNT), 5p15.33 (TERT), 11q13.3 (CCND1), 19q12 (CCNE1) and 8q24.1 (MYC) were frequently subclonal yet appeared to be clonal within single samples. Analysis of an independent series of 1,024 metastatic samples revealed that 13 focal SCNAs were enriched in metastatic samples, including gains in chromosome 8q24.1 (encompassingMYC) in clear cell renal cell carcinoma and chromosome 11q13.3 (encompassingCCND1) in HER2(+)breast cancer. Chromosomal instability may enable the continuous selection of SCNAs, which are established as ordered events that often occur in parallel, throughout tumour evolution. Chromosomal instability enables the continuous selection of somatic copy number alterations, which are established as ordered events that often occur in parallel, throughout tumour evolution and metastasis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据